Incyte (INCY) Acquires Jakafi Commercialization, Development Rights from Lilly (LLY)
Tweet Send to a Friend
Incyte Corporation (Nasdaq: INCY) announced it has acquired the rights to develop and commercialize ruxolitinib (Jakafi), its proprietary JAK1/JAK2 inhibitor ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE